Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

buprenorphine

B-PATCH

buprenorphine (B-PATCH) is a kappa opioid receptor agonist. Associated with Indivior Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved Nervous system (N07) N07BC51
US status approved
Patents linked 20
Pipeline programs 61
News articles 0
Drug details — buprenorphine
US status
approved
Class
Nervous system (N07)
Route
SUBCUTANEOUS
Patents
20
Programs
61
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

buprenorphine (B-PATCH) is a kappa opioid receptor agonist. Associated with Indivior Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.

Key facts

INN buprenorphine
Brand B-PATCH
Mechanism Kappa opioid receptor agonist
Target Kappa-type opioid receptor
Therapeutic class Nervous system (N07)
Route SUBCUTANEOUS
Formulation FILM, EXTENDED RELEASE
ATC code N07BC51
Originator Indivior Pty Ltd

Mechanism of action

Kappa opioid receptor agonist

Primary target: Kappa-type opioid receptor

Approval history

Authority Status Date
FDA approved —
EMA approved —
TGA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Buprenorphine Phase 3 · BRIGHT MINDS BIOSCIENCES · Opioid-use Disorder
  2. Buprenorphine Phase 3 · BRIGHT MINDS BIOSCIENCES · Cocaine-Related Disorders
  3. Buprenorphine Phase 3 · BRIGHT MINDS BIOSCIENCES · Heroin Dependence
  4. Buprenorphine + Naltrexone Phase 3 · BRIGHT MINDS BIOSCIENCES · Cocaine Dependence
  5. Buprenorphine +OTP Phase 3 · BRIGHT MINDS BIOSCIENCES · Heroin Addiction
  6. Buprenorphine Injection Phase 3 · BRIGHT MINDS BIOSCIENCES · Opioid-Related Disorders
  7. Buprenorphine Transdermal System Phase 3 · Chinese Academy of · Disease (or Disorder); Intervertebral Disc, With Myelopathy
  8. Buprenorphine/Naloxone Phase 3 · BRIGHT MINDS BIOSCIENCES · HIV Infections

Related & competitor drugs

Browse all drugs
  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine hydrochloride Mu opioid receptor agonist
  6. caffeine citrate Nervous system (N06)

Related patents

Browse patents Indivior Pty Ltd patent hub

  1. US 12226429

    Highly active compounds against COVID-19

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11839611

    Buprenorphine dosing regimens

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11813278

    Highly active compounds against COVID-19

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11738038

    Highly active compounds against COVID-19

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11707480

    Highly active compounds against COVID-19

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11000520

    Buprenorphine dosing regimens

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10888529

    Vehicles for the transfection of miRNAs

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10874687

    Highly active compounds against COVID-19

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10646484

    Methods to treat opioid use disorder

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10610597

    Polycarbonates bearing aromatic N-heterocycles for drug delivery

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10592168

    Injectable flowable composition comprising buprenorphine

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10584135

    Substituted 3,6-diazabicyclo[3.2.0]heptanes

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10558394

    Injectable flowable composition comprising buprenorphine

    Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10517864

    Sustained-release buprenorphine solutions

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10198218

    Injectable flowable composition comprising buprenorphine

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10172849

    Compositions comprising buprenorphine

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10149912

    Dehydrated hydrogel inclusion complex

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10022367

    Sustained-release buprenorphine solutions

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9919027

    Lipid nanoparticle of polymyxin

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9827241

    Injectable flowable composition comprising buprenorphine

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is buprenorphine?

buprenorphine (B-PATCH) is a kappa opioid receptor agonist. Associated with Indivior Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.

What is the brand name for buprenorphine?

B-PATCH is a marketed brand name for buprenorphine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of buprenorphine?

buprenorphine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.